{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.1"},{"groupId":"OG001","value":"3.8"},{"groupId":"OG002","value":"0.8"}]}],"title":"100% (seizure free)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0"},{"groupId":"OG001","value":"15.4"},{"groupId":"OG002","value":"5.0"}]}],"title":"≥ 75 to <100 (75% responder)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.1"},{"groupId":"OG001","value":"20.8"},{"groupId":"OG002","value":"9.2"}]}],"title":"≥ 50 to <75 (50% responder)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.9"},{"groupId":"OG001","value":"30.0"},{"groupId":"OG002","value":"22.7"}]}],"title":"≥ 25 to <50 (25% responder)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.0"},{"groupId":"OG001","value":"18.5"},{"groupId":"OG002","value":"41.2"}]}],"title":">-25 to <25 (No change)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.8"},{"groupId":"OG001","value":"11.5"},{"groupId":"OG002","value":"20.2"}]}],"title":"≤ -25 (Exacerbation)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"},{"groupId":"OG002","value":"0.8"}]}],"title":"Missing (missing)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"117"},{"groupId":"OG001","value":"130"},{"groupId":"OG002","value":"119"}],"units":"Participants"}],"description":"Comparison of percentage of patients in six categories of seizure reduction from baseline (≤ -25% (exacerbation); \\> -25% to \\< 25% (no change); ≥ 25% to \\< 50%; ≥ 50% to \\< 75%; ≥ 75% to \\< 100%; 100% (seizure-freedom)) in the everolimus low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm during maintenance period of the core phase","groups":[{"description":"Participants were randomized to receive everolimus dispersible tablets for oral suspension with titration to a low trough (LT) range of 3 to 7 ng/mL","id":"OG000","title":"Everolimus LT Target of 3 to 7 ng/mL"},{"description":"Participants were randomized to receive everolimus dispersible tablets for oral suspension with titration to a high trough (HT) range of 9 to 15 ng/mL","id":"OG001","title":"Everolimus HT Target of 9 to 15 ng/mL"},{"description":"Participants were randomized to receive placebo dispersible tablets for oral suspension.","id":"OG002","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"The Full Analysis Set (FAS) comprised all patients to whom study treatment was assigned by randomization","reportingStatus":"POSTED","timeFrame":"Baseline (8-week period before randomization), Week 7 to 18 (12-week maintenance period of the core phase)","title":"Core Phase: Distribution of Reduction From Baseline in Seizure Frequency","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}